Last reviewed · How we verify
NCT05074706: Hema-C19-Vax
Evaluation of the Immune Response to Sars-Covid-19 Vaccines in Haematological Patients: Prospective Single Center Study
trial testing IgG antibodies to Sars-Cov-2 in Hematologic Diseases in 700 participants. Completed in 15 June 2022.
15 June 2022
Quick facts
| Lead sponsor | University of Milano Bicocca |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 700 |
| Start date | 9 June 2021 |
| Primary completion | 15 June 2022 |
| Estimated completion | 15 June 2022 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- IgG antibodies to Sars-Cov-2 — full drug profile →
- QuantiFERON SARS-CoV-2 test — full drug profile →
Conditions studied
- Hematologic Diseases — all drugs for Hematologic Diseases →
Sponsor
University of Milano Bicocca
Who can join
18 and older, any sex, with Hematologic Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The main objective of this study is to investigate the humoral immune response to COVID-19 vaccines in haematological patients, by testing SARS-CoV-2 seroconversion
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Humoral and cellular immune response in patients with hematological disorders after two doses of BNT162b2 mRNA COVID-19 vaccine: A single-center prospective observational study (NCT05074706).
Bossi E, Aroldi A, Borin LM, Verga L, et al · · 2022 · cited 3× · PMID 36248617 · DOI 10.1002/jha2.544
Verify or expand the search:
- PubMed search for NCT05074706
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hematologic Diseases
Currently open trials in the same condition.
- NCT07257640 — IL-5 CAR-T Cell Therapy for Refractory/Relapsed Eosinophilic Leukemia · Phase 1 · recruiting
- NCT06487247 — HEME Home Transfusion Program · NA · recruiting
- NCT05414045 — Autologous Testicular Tissue Transplantation · NA · recruiting
- NCT06613425 — Clinical Study of Combined Platelet Transfusion · Phase 4 · recruiting
- NCT06271252 — A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study · Phase 1 · recruiting
Other University of Milano Bicocca trials
Trials by the same sponsor.
- NCT07257705 — Pilot Trial of a Clinical Decision-Support App for Managing Emergencies Among Clinicians in a Rural Ugandan Hospital · NA · completed
- NCT07457138 — Lombard Cohort of Brain Health Services · recruiting
- NCT07407608 — ABlative Radiotherapy (for) Unfavorable Prostate Tumors 2.0 · recruiting
- NCT07479914 — Art of Memory for Cognitive Enhancement in the Monza Brain Health Service · NA · active not recruiting
- NCT07424066 — Non-invasive Vibratory Stimulation of the Knee Muscles for the Improvement of the Somatosensory Input and Motor Performa · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05074706 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Milano Bicocca
- Last refreshed: 25 January 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05074706.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing